Abstract

Klebsiella (K.) pneumoniae is a common cause of pneumonia-derived sepsis in human and is associated with high morbidity and mortality. The microbiota promotes and maintains host immune homeostasis during bacterial infections. However, the mechanisms by which the gut microbiota affects immune responses in the lung still remain poorly understood. Here, we performed cecal metabolomics sequencing and fecal 16s rRNA sequencing in K. pneumoniae-infected mice and uninfected controls and showed that K. pneumoniae infection led to profound alterations in the gut microbiome and thus the cecal metabolome. We observed that the levels of Lactobacillus reuteri and Bifidobacterium pseudolongum were significantly decreased in K. pneumoniae-infected mice. Spearman correlation analysis showed that alterations in the richness and composition of the gut microbiota were associated with profound changes in host metabolite concentrations. Further, short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, were detected in cecal contents and serum by gas chromatography-mass spectrometry (GC-MS). We observed that the concentrations of these three SCFAs were all lower in the infected groups than in the untreated controls. Lastly, oral supplementation with these three SCFAs reduced susceptibility to K. pneumoniae infections, as indicated by lower bacterial burdens in the lung and higher survival rates. Our data highlight the protective roles of gut microbiota and certain metabolites in K. pneumoniae-pneumonia and suggests that it is possible to intervene in this bacterial pneumonia by targeting the gut microbiota.

Highlights

  • K. pneumoniae is a severe, multidrug-resistant (MDR) pathogen that currently has high morbidity and mortality owing to the limited availability of treatment options [1, 2]

  • We investigated whether oral supplementation with short-chain fatty acids (SCFAs) or SCFAderived bacteria might be effective in bacterial pneumonia treatment

  • We identified, based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, 149 metabolites that differed in abundance between K. pneumoniae-infected mice and uninfected controls, including both host-derived and bacterially derived metabolites (Figures 1A,B)

Read more

Summary

Introduction

K. pneumoniae is a severe, multidrug-resistant (MDR) pathogen that currently has high morbidity and mortality owing to the limited availability of treatment options [1, 2]. The role of gut microbiota in mediating the host immune/inflammatory responses locally and systemically has become recognized over the last two decades. Alterations in the microbiome and metabolome and their interaction with the immune, endocrine, and mucosal systems are associated with a wide array of illnesses, and vice versa, diseases, and pathological conditions tend to cause gut microbiota dysbiosis and altered production of microbial metabolites, leading to dysregulation of the metabolism and immune system [3,4,5,6,7]. Disruption of the gut–lung axis has already been associated with respiratory diseases [10,11,12,13,14], the mechanisms by which the gut microbiota affects the immune responses in distal lung, still remain poorly characterized

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.